Wavelength is a leading developer and manufacturer of generic APIs and finished dose forms (“FDF”) with operations primarily located in Israel. Wavelength supports a global, blue-chip customer base and has a broad array of products that leverage its specialized manufacturing capabilities (including cytotoxic, steroid and high potency) and core competency in complex chemistries.

SK Capital acquired Wavelength in November 2017.

For more information, please visit: http://www.wavelengthpharma.com/